Agf Investments Inc. Incyte Corp Transaction History

Agf Investments Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$66.02 - $79.71 $223,939 - $270,376	-3,392 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$63.34 - $74.11 $62,833 - $73,517	992 Added 41.33%	3,392 $249,000
Q3 2021 Nov 10, 2021	BUY	$68.67 - $84.02 $18,266 - $22,349	266 Added 12.46%	2,400 $165,000
Q2 2021 Aug 10, 2021	SELL	$79.87 - $87.53 $7,827 - $8,577	-98 Reduced 4.39%	2,134 $180,000
Q1 2021 May 14, 2021	SELL	$76.02 - $100.5 $14,443 - $19,095	-190 Reduced 7.84%	2,232 $181,000
Q4 2020 Feb 08, 2021	SELL	$80.74 - $97.7 $112,874 - $136,584	-1,398 Reduced 36.6%	2,422 $211,000
Q3 2020 Nov 12, 2020	BUY	$85.07 - $109.69 $324,967 - $419,015	3,820 New	3,820 $343,000

642

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Agf Investments Inc., based on Form 13F filings with the SEC.

Stay updated on Agf Investments Inc. with notifications on news.